{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:32:45Z","timestamp":1790195565363,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","primary-care-diabetes.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Primary Care Diabetes"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.pcd.2019.01.003","type":"journal-article","created":{"date-parts":[[2019,1,31]],"date-time":"2019-01-31T22:53:27Z","timestamp":1548975207000},"page":"204-211","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Network meta-analysis of nine large cardiovascular outcome trials of new antidiabetic drugs"],"prefix":"10.1016","volume":"13","author":[{"given":"Osamah M.","family":"Alfayez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majed S.","family":"Al Yami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohannad","family":"Alshibani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad B.","family":"Fallatah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasser M.","family":"Al Khushaym","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razan","family":"Alsheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nimer","family":"Alkhatib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pcd.2019.01.003_bib0005","series-title":"National Diabetes Statistics Report, 2017","author":"Centers for Disease Control and Prevention","year":"2017"},{"issue":"18","key":"10.1016\/j.pcd.2019.01.003_bib0010","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1056\/NEJMoa1504347","article-title":"Excess mortality among persons with type 2 diabetes","volume":"373","author":"Tancredi","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 1","key":"10.1016\/j.pcd.2019.01.003_bib0015","first-page":"S104","article-title":"9. Cardiovascular disease and risk management: standards of medical care in diabetes-2018","volume":"41","author":"American Diabetes Association","year":"2018","journal-title":"Diabetes Care"},{"issue":"356","key":"10.1016\/j.pcd.2019.01.003_bib0020","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"2007","author":"Nissen","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pcd.2019.01.003_bib0025","series-title":"Guidance for Industry Diabetes Mellitus\u2014Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes","author":"Food US","year":"2008"},{"issue":"14","key":"10.1016\/j.pcd.2019.01.003_bib0030","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.pcd.2019.01.003_bib0035","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369","author":"White","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.pcd.2019.01.003_bib0040","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"375","key":"10.1016\/j.pcd.2019.01.003_bib0045","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"2016","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.pcd.2019.01.003_bib0050","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.pcd.2019.01.003_bib0055","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.pcd.2019.01.003_bib0060","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.pcd.2019.01.003_bib0065","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.pcd.2019.01.003_bib0070","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.pcd.2019.01.003_bib0075","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations PRISMA extension for network meta-analysis","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann. Intern. Med."},{"issue":"2","key":"10.1016\/j.pcd.2019.01.003_bib0080","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.dss.2012.10.005","article-title":"ADDIS: a decision support system for evidence-based medicine","volume":"55","author":"Van Valkenhoef","year":"2013","journal-title":"Decis. Support Syst."},{"issue":"7\u20138","key":"10.1016\/j.pcd.2019.01.003_bib0085","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis","volume":"29","author":"Dias","year":"2010","journal-title":"Stat. Med."},{"issue":"3","key":"10.1016\/j.pcd.2019.01.003_bib0090","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1177\/0962280207080643","article-title":"Evaluation of networks of randomized trials","volume":"17","author":"Salanti","year":"2008","journal-title":"Stat. Methods Med. Res."},{"issue":"24","key":"10.1016\/j.pcd.2019.01.003_bib0095","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"ADVANCE Collaborative Group","year":"2008","journal-title":"N. Engl. J Med."},{"issue":"15","key":"10.1016\/j.pcd.2019.01.003_bib0100","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.pcd.2019.01.003_bib0105","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"Action to Control Cardiovascular Risk in Diabetes Study Group","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.pcd.2019.01.003_bib0110","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/1753-0407.12524","article-title":"American diabetes association standards of medical care in diabetes 2017","volume":"9","author":"Marathe","year":"2017","journal-title":"J. Diabetes"},{"key":"10.1016\/j.pcd.2019.01.003_bib0115","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ijcard.2016.12.113","article-title":"Cardiovascular safety of incretin-based therapy for type 2 diabetes: a meta-analysis of randomized trials","volume":"230","author":"Mahmoud","year":"2017","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.pcd.2019.01.003_bib0120","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.ijcard.2017.12.039","article-title":"Network meta-analysis of cardiovascular outcomes in randomized controlled trials of new antidiabetic drugs","volume":"254","author":"Fei","year":"2018","journal-title":"Int. J. Cardiol."},{"issue":"15","key":"10.1016\/j.pcd.2019.01.003_bib0125","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/jama.2018.3024","article-title":"Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"319","author":"Zheng","year":"2018","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.pcd.2019.01.003_bib0130","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.2337\/dc16-0303","article-title":"Cardiovascular mortality in patients with type 2 diabetes and recent acute coronary syndromes from the EXAMINE trial","volume":"39","author":"White","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pcd.2019.01.003_bib0135","series-title":"FDA Drug Safety Communication: FDA Adds Warnings about Heart Failure Risk to Labels of Type 2 Diabetes Medicines Containing Saxagliptin and Alogliptin","author":"US Food and Drug Administration","year":"2016"},{"issue":"1","key":"10.1016\/j.pcd.2019.01.003_bib0140","doi-asserted-by":"crossref","first-page":"89","DOI":"10.4158\/EP161481.RA","article-title":"Cardiovascular outcome trials of the incretin-based therapies: what do we know so far?","volume":"23","author":"Mora","year":"2016","journal-title":"Endocr. Pract."},{"issue":"2","key":"10.1016\/j.pcd.2019.01.003_bib0145","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S2213-8587(17)30412-6","article-title":"Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"Bethel","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"1","key":"10.1016\/j.pcd.2019.01.003_bib0150","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s10557-018-6773-2","article-title":"GLP-1 receptor agonists and cardiovascular disease: a meta-analysis of recent cardiac outcome trials","volume":"32","author":"Jia","year":"2018","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.pcd.2019.01.003_bib0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.hlc.2018.03.018","article-title":"Update in cardiovascular safety of glucagon like peptide-1 receptor agonists in patients with type 2 diabetes. A mixed treatment comparison meta-analysis of randomised controlled trials","author":"Al Yami","year":"2018","journal-title":"Heart, Lung and Circ."},{"issue":"Suppl. 1","key":"10.1016\/j.pcd.2019.01.003_bib0160","first-page":"S85","article-title":"8. Pharmacologic approaches to glycemic treatment: Standards of medical care in diabetes-2018","volume":"41","author":"American Diabetes Association","year":"2018","journal-title":"Diabetes Care"}],"container-title":["Primary Care Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1751991818303097?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1751991818303097?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T23:57:26Z","timestamp":1761695846000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1751991818303097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S1751991818303097"],"URL":"https:\/\/doi.org\/10.1016\/j.pcd.2019.01.003","relation":{},"ISSN":["1751-9918"],"issn-type":[{"value":"1751-9918","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Network meta-analysis of nine large cardiovascular outcome trials of new antidiabetic drugs","name":"articletitle","label":"Article Title"},{"value":"Primary Care Diabetes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcd.2019.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Primary Care Diabetes Europe. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}